Abiopharma

🔍 Basi Ramitpal K (Executive)

Company: INCYTE CORP (INCY)

Report Date: 2025-08-25

Detailed Transactions and Holdings:

• Acquired 6,506 shares of Common Stock (Direct)
  Date: 2025-08-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 6,506.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 16,265 shares of Performance Shares (Derivative)
  Date: 2025-08-25 | Code: A | Expires: 2028-08-25 | equity_swap_involved: 0 | shares_owned_after: 16,265.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Acquired 29,230 shares of Employee Stock Option (right to buy) at $84.76 per share (Derivative)
  Date: 2025-08-25 | Code: A | Expires: 2035-08-24 | equity_swap_involved: 0 | shares_owned_after: 29,230.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
• F2: Includes the August 25, 2025 aggregate grant of 6,506 shares of common stock.
• F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
• F4: The August 25, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.